 The reform study is a prospective, longitudinal cohort study designed to identify biomarkers that can predict response to a renumab in patients with migraine. The study enrolled 751 participants, with a mean age of 43.8 years, of which 88.8% were female. At enrollment, 64.7% were diagnosed with chronic migraine, and 30.2% had a history of aura. The mean monthly migraine days, MMDs, was 14.5. Additionally, 48.5% of participants were taking concomitant preventive medication, and 39.9% had failed at least for preventive medications. This study provides valuable insight into the demographics and clinical characteristics of patients with migraine who are likely to benefit from a renumab. This article was authored by William Christian Colson, Hock and Ashina, Christopher C. Cullen, and others. We are article.tv, links in the description below.